Conventional ocular drug delivery system i.e., eye drops, ointments, gels etc., had become less popular pertaining to their disadvantages like evaporation by tears, pre-corneal loss, drug metabolism, drug-protein interaction, drainage, sticking of eye lids, induced lacrimation, poor patient compliance, systemic side effect and blurred vision etc. That’s why fundamentals of controlled release by means of ocular inserts were utilized to increase problem pre-corneal drug residence time.
This project title “Formulation and Evaluation of Ocuserts of Ciprofloxacin HCl” revealed following results:
Compatibility study using FTIR was performed to check the compatibility of drug with various excipient. Characteristics peaks obtained with pure drug were compared with that produced with different excipients that confirmed the compatibility of drug with excipients.
Ocusert of Ciprofloxacin HCl was prepared using different material i.e., PVP K-30, PVA, PEG 400 and glycerin.
Prepared ocuserts were evaluated for various parameters viz., percentage moisture loss, percentage moisture absorbs, thickness, weight variation, drug content and In-vitro diffusion.
The percentage (%) moisture absorption and loss of ocular insert were found to be 26% and 27% respectively.
The thickness of ocular insert was found to be uniformed and its mean while measuring at different points was found to be 0.124mm.
The weight of ocular inserts was found to be in the range of 12.2 - 12.6mg which indicated decent distribution of the drug, polymer and plasticizer.
The drug content of ocular insert was found to be 99.89%.
Percentage drug release from Ciprofloxacin HCl Ocusert was found to be 41.969% in 8 hr.
It was concluded that prepared Ocusert of Ciprofloxacin HCl could be a better alternative to conventional ocular formulations that retained on ocular surface for longer duration and released drug in controlled manner.
Gastro retentive drug delivery system (GRDDS)Shweta Nehate
Oral route is the most acceptable route for drug administration. Apart from conventional dosage forms several other forms were developed in order to enhance the drug delivery for prolonged time period and for delivering drug to a particular target site. Gastro-retentive drug delivery system (GRDDS) has gainned immense popularity in the field of oral drug delivery recently. it is a widely employed approach to retain the dosage form in the stomach for an extended period of time and release the drug slowly that can address many challenges associated with conventional oral delivery, including poor bioavailability. different innovative approaches are being applied to fabricate GRDDS. Gastroretentive drug delivery is an approach to prolong gastric residence time, there by targeting site-specific drugs release in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form into stomach and by releasing the in controlled manner.
Gastro retentive drug delivery system (GRDDS)Shweta Nehate
Oral route is the most acceptable route for drug administration. Apart from conventional dosage forms several other forms were developed in order to enhance the drug delivery for prolonged time period and for delivering drug to a particular target site. Gastro-retentive drug delivery system (GRDDS) has gainned immense popularity in the field of oral drug delivery recently. it is a widely employed approach to retain the dosage form in the stomach for an extended period of time and release the drug slowly that can address many challenges associated with conventional oral delivery, including poor bioavailability. different innovative approaches are being applied to fabricate GRDDS. Gastroretentive drug delivery is an approach to prolong gastric residence time, there by targeting site-specific drugs release in the upper gastrointestinal tract (GIT) for local or systemic effects. It is obtained by retaining dosage form into stomach and by releasing the in controlled manner.
Mucoadhesive drug delivery system interact with the mucus layer covering the mucosal epithelial surface, & mucin molecules & increase the residence time of the dosage form at the site of the absorption.
Mucoadhesive drug delivery system is a part of controlled delivery system.
Since the early 1980,the concept of Mucoadhesion has gained considerable interest in pharmaceutical technology.
combine mucoadhesive with enzyme inhibitory & penetration enhancer properties & improve the patient complaince.
MDDS have been devloped for buccal ,nasal,rectal &vaginal routes for both systemic & local effects.
Hydrophilic high mol. wt. such as peptides that cannot be administered & poor absorption ,then MDDS is best choice.
Mucoadhesiveinner layers called mucosa inner epithelial cell lining is covered with viscoelasticfluid
Composed of water and mucin.
Thickness varies from 40 μm to 300 μm
General composition of mucus
Water…………………………………..95%
Glycoproteinsand lipids……………..0.5-5%
Mineral salts……………………………1%
Free proteins…………………………..0.5-1%
The mechanism responsible in the formation of mucoadhesive bond
Step 1 : Wetting and swelling of the polymer(contact stage)
Step 2 : Interpenetration between the polymer chains and the mucosal membrane
Step 3 : Formation of bonds between the entangled chains (both known as consolidation stage)
Electronic theory
Wetting theory
Adsorption theory
Diffusion theory
Fracture theory
Advantages over other controlled oral controlled release systems by virtue of prolongation of residence of drug in GIT.
Targeting & localization of the dosage form at a specific site
-Painless administration.
-Low enzymatic activity & avoid of first pass metabolism
If MDDS are adhere too tightlgy because it is undesirable to exert too much force to remove the formulation after use,otherwise the mucosa could be injured.
-Some patient suffers unpleasent feeling.
-Unfortunately ,the lack of standardized techniques often leads to unclear results.
-costly drug delivery system
Mucoadhesive drug delivery system interact with the mucus layer covering the mucosal epithelial surface, & mucin molecules & increase the residence time of the dosage form at the site of the absorption.
Mucoadhesive drug delivery system is a part of controlled delivery system.
Since the early 1980,the concept of Mucoadhesion has gained considerable interest in pharmaceutical technology.
combine mucoadhesive with enzyme inhibitory & penetration enhancer properties & improve the patient complaince.
MDDS have been devloped for buccal ,nasal,rectal &vaginal routes for both systemic & local effects.
Hydrophilic high mol. wt. such as peptides that cannot be administered & poor absorption ,then MDDS is best choice.
Mucoadhesiveinner layers called mucosa inner epithelial cell lining is covered with viscoelasticfluid
Composed of water and mucin.
Thickness varies from 40 μm to 300 μm
General composition of mucus
Water…………………………………..95%
Glycoproteinsand lipids……………..0.5-5%
Mineral salts……………………………1%
Free proteins…………………………..0.5-1%
The mechanism responsible in the formation of mucoadhesive bond
Step 1 : Wetting and swelling of the polymer(contact stage)
Step 2 : Interpenetration between the polymer chains and the mucosal membrane
Step 3 : Formation of bonds between the entangled chains (both known as consolidation stage)
Electronic theory
Wetting theory
Adsorption theory
Diffusion theory
Fracture theory
Advantages over other controlled oral controlled release systems by virtue of prolongation of residence of drug in GIT.
Targeting & localization of the dosage form at a specific site
-Painless administration.
-Low enzymatic activity & avoid of first pass metabolism
If MDDS are adhere too tightlgy because it is undesirable to exert too much force to remove the formulation after use,otherwise the mucosa could be injured.
-Some patient suffers unpleasent feeling.
-Unfortunately ,the lack of standardized techniques often leads to unclear results.
-costly drug delivery system
Transdermal Drug Delivery System [TDDS]Sagar Savale
Management of illness through medication has entered an era of rapid growth. A variety of means by which drugs are delivered to the human body for the therapy such as tablets, capsules, injections, aerosols, creams, ointments, suppositories, liquids etc. are referred as a conventional drug formulations. Among many pharmaceutical dosage forms, continuous intravenous infusion at preprogrammed rate has been recognized as a superior mode of drug delivery. At present, the most common form of delivery of drugs is the oral route. It has the notable advantage of easy administration.
Glass as a packaging material in pharmaceutical packagingShweta Shelke
This presentation gives a brief idea about the types of glasses used in pharmaceutical industry and its intended use. Different tests used for assuring its quality for intended use.
Formulation and Evaluation of Floating Tablet of Metoprolol Succinateijtsrd
The aim of the present work is Formulation and Evaluation of Floating Tablet of Metoprolol Succinate. Metoprolol Succinate is a BCS class I drug used in the treatment of Angina pectoric, Heart attack, Hypertension and has short half life 3 7hours. In the present study it was planned to prepare sustained release floating tablets of Metoprolol succinate by using HPMC E5 and Gum Karaya excipients. The procured sample of drug was authenticated by pre formulation study like melting point, IR spectra, UV analysis were done. Results of pre formulation studies show that Metoprolol Succinate was pure and complies with standard. Prior to compression, the powder blend were evaluated for angle of repose, bulk density, tapped density, compressibility index, Hausners ratio. Results of pre formulation studies show that Metoprolol Succinate was pure and complies with standard. Formulations were evaluated for various evaluation parameters like hardness, thickness, weight variation, friability, drug content, floating lag time, floating time, swelling index and in vitro drug release. From the results of evaluation parameters it was observed that formulation F6 shows best results for floating lag time 4min floating time up to 12 hours and consistent drug release 96.15 as compared to other formulations. So formulation F6 was finalized as a optimized formulation for further study. On the basic of above finding it was concluded that sustained release floating drug delivery system was successfully achieved. Neeta. V. Jadhav | Prof. Mr. Prashant Khade | Dr. Ashok Bhosale "Formulation and Evaluation of Floating Tablet of Metoprolol Succinate" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-5 , August 2022, URL: https://www.ijtsrd.com/papers/ijtsrd50409.pdf Paper URL: https://www.ijtsrd.com/pharmacy/pharmaceutics/50409/formulation-and-evaluation-of-floating-tablet-of-metoprolol-succinate/neeta-v-jadhav
Formulation and evaluation of microspheres with aceclofenacSagar Savale
Aceclofenac is an analgesic and anti-inflammatory drug that reduces fever, pain, and inflammation in rheumatoid
arthritis, osteoarthritis and ankylosing spondylitis. Aceclofenac has higher anti-inflammatory action than
conventional NSAIDs. Development of microspheres is a promising technology for controlled release and drug
targeting. Various types of microspheres such as bio-adhesive, magnetic, floating, radioactive and polymeric
microspheres are developed for various purposes. Microspheres occupied a central place in novel drug delivery, it
can targeted and localized drug delivery system. This Aceclofenac Microsphere is Prepared by using Spray drying
Technique in which release rate of drug is mainly depends on formulation composition (Eudragit RS 30 D and
Ethyl Cellulose (1:2 ratio)). Formulated microspheres were characterized for particle size, encapsulation efficiency
and In vitro studies. The optimum drug-to-polymer ratio and feed flow rate is responsible for higher percent yield,
smaller particle size and maximum encapsulation efficiency.
Introduction
Anatomy and physiology of human eye
Ocular delivery system
Optimum characters of ophthalmic drugs
Routes of ophthalmic drugs
Mechanism of ocular drug absorption
Barriers and fate of ocular drug delivery
Formulation consideration of ocular dosage forms
Evaluation tests
References
Background: The main objective of present research work is to formulate the Carbamazepine Fast Dissoving tablets. Carbamazepine, an
antiepileptic, belongs to BCS Class-II and used to control some types of seizures in the treatment of epilepsy and Neuropathic Pain by
blocking use-dependent sodium channels. Methods: The Fast Dissoving tablets of Carbamazepine were prepared employing different
concentrations of Crospovidone and Croscarmellose sodium in different combinations as a Sperdisintegrants by Direct Compression technique
using 32
factorial design. The concentration of Crospovidone and Croscarmellose sodium was selected as independent variables, X1
and X2 respectively whereas, wetting time, Disintegration time, t
50% ,t90%were selected as dependent variables. Results and Discussion:
Totally nine formulations were designed and are evaluated for hardness, friability, thickness, Assay, Wetting time, Disintegration time, Invitro
drug release. From the Results concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-vitro
dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like intercept (a), slope (b) &
regression coefficient (r) were calculated. Polynomial equations were developed for Wetting time, Disintegration time, t50%, t90%. Validity of
developed polynomial equations were verified by designing 2 check point formulations (C1
, C2
). According to SUPAC guidelines the
formulation (F5
) containing combination of 9.375% Crospovidone and 9.375% Croscarmellose, is the most similar formulation (similarity factor
f
2
=82.675, dissimilarity factor f1
= 2.049 & No significant difference, t= 0.041) to marketed product (TEGRETOL-100). Conclusion: The
selected formulation (F5
) follows First order, Higuchi’s kinetics, mechanism of drug release was found to be Non-Fickian Diffusion (n= 0.665).
KEYWORDS: Carbamazepine, 3
2Factorial Design, Crospovidone , croscarmellose Sodium, Wetting Time, Disintegration Time.
Abstract:
The Chronopharmacotherapy the drug administration is synchronised with circadian rhythms Formulation development of Microspheres is more reliable formulation as compare to single type dosage formulation due to it avoids dose dumping, as per required drug release profile is achieved For microspheres many polymers are used such as albumin, gelatine, starch, Eudragit, Polyacrylamide (“PAM”) these material loading capacity is high. Micro sponges which are Spherical are called as micro-balloons. Due to its hollow structure it shows good floating properties. In these systems use of Carbon-dioxide (CO2) as gas generating system which are used for floating purpose. The objective of present investigation is to prepared and evaluate a floating pulsatile drug delivery system of Aceclofenac. The strategy adopted for microspheres containing Aceclofenac as a material were prepared by emulsion solvent diffusion technique. Drug and polymer were mixed in dichloromethane and ethanol at 1:1 ratio. The drug and polymer solution were poured in water 50% W/V polyvinyl alcohol maintained at 30-40 C and the solution was stir at 500rpm using mechanical stirrer, The microspheres obtain were washed repeatedly with water until free from poly vinyl alcohol. The developed formulations were evaluated yield of floating microspheres particle size and shape, drug entrapment efficiency in-vitro evolution of floating ability, in-vitro drug release study. On the basis of these evolution parameters it was found that optimised floating pulsatile release formulation F7 showed higher drug entrapment efficiency floating time 6.8 minutes and the drug and polymer 32 1:3 ratio the particle size was increased.
Key Words: Chronopharmacotherapy, Floating pulsatile drug delivery, Aceclofenac.
The main objective of the present research work is to formulate the Clopidogrel Fast Dissolving tablets. Clopidogrel, an antiplatelet drug, belongs to BCS Class-II and used to control Heart attack, Hypertension by inhibiting Platelet activation and aggregation .The Fast Dissolving tablets of Clopidogrel were prepared employing different concentrations of Crospovidone and Croscarmellose sodium in different combinations as a Superdisintegrant by Direct Compression technique using 32 factorial design. The concentration of Crospovidone and Croscarmellose sodium was selected as independent variables, X1 and X2 respectively whereas, wetting time, Disintegration time, t50%, t90% were selected as dependent variables. Totally nine formulations were designed and evaluated for hardness, friability, thickness, Assay, Wetting time, Disintegration time, and in-vitro drug release. From the Results it was concluded that all the formulation were found to be with in the Pharmacopoeial limits and the in-vitro dissolution profiles of all formulations were fitted into different Kinetic models, the statistical parameters like intercept (a), slope (b) and regression coefficient (r) were calculated. Polynomial equations were developed for Wetting time, Disintegration time, t50%, t90%. Validity of developed polynomial equations was verified by designing 2 check point formulations (C1, C2). According to SUPAC guidelines, the formulation (F5) containing combination of 15% Crospovidone and 15% Croscarmellose, is the most similar formulation (similarity factor f2=91.3936, dissimilarity factor f1= 1.203& No significant difference, t= -0.00062) to marketed product (PLAVIX-75). The selected formulation (F1) follows First order, Higuchi’s kinetics, mechanism of drug release found to be Fickian Diffusion (n= 0.226).
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
FORMULATION AND EVALUATION OF OCUSERTS OF CIPROFLOXACIN HCl
1. A
PRESENTATION
ON
FORMULATION AND EVALUATION OF OCUSERTS OF CIPROFLOXACIN HCl
Submitted for the partial fulfilment of the award of the degree of
Bachelor of Pharmacy
By
MOHAMMAD ADIL
Enrollment No. TPH1102033Approved by Supervised by
PROF. (DR.) K. K. JHA MRS. SHAWETA SHARMA
(Director) (Asst. Prof.)
TEERTHAKER MAHAVEER COLLEGE OF PHARMACY
TEERTHANKER MAHAVEER UNIVERSITY MORADABAD
2015- 2016
1
2. INTRODUCTION
Eye is an essential organ with unique qualities and enable us to see the world.
Eye sicknesses can influence the body and consequently led to loss of vision also.
Therefore, many traditional and new ocular drug delivery systems are available.
Most commonly available ophthalmic preparations i.e. eye drops and ointments covers about 70% of
the total formulations in market.
From conventional dosage forms, just a little amount is available for its therapeutic effect resulting in
frequent dosing.
That’s why to overthrown these issues, newer pharmaceutical formulation such as In-situ gel,
nanoparticles, liposomes, nanosuspension, microemulsion, iontophoresis and ocular inserts have been
developed to increase the bioavailability of the drug in sustained and controlled manner.
2
3. CLASSIFICATION OF OCULAR DRUG DELIVERY
SYSTEMS: -
Ocular drug delivery system are classified as:
• LIQUIDS: - Sprays, sol-gel systems, suspensions & solutions.
• SOLIDS: - Ocular inserts, artificial tear inserts, contact lenses, filter paper strips & corneal shield.
• SEMI-SOLIDS: Gels & ointments.
• MISCELLANEOUS: Ocular iontophoresis, Muco-adhesive dosage forms & vesicular systems.
3
4. OCUSERTS:
Ocular inserts have been developed through which the drug is
delivered at a near constant known rate based on diffusional
mechanisms.
Minimizes side effects by avoiding excessive absorption peaks.
The delivery of pilocarpine by such an insert was
commercialized in 1975 (ocuserts Pilo) by Alza corporation.
The ocuserts was designed to be placed in the lower cul-de-sac
to provide a weekly dose of pilocarpine and removed &
replaced by a new one after completion of time.
The near zero-order rate delivery is based on the selection of an
non-eroding copolymer membrane enclosing the drug reservoir.
Placement of ocusert into eye
4
5. ADVANTAGES OF OCUSERTS:
Increased contact time that led to enhanced bioavailability.
Possibility of providing a prolonged drug release and in consequence a better efficacy.
Administration of a precise dose in the eye and thus an improved therapy.
Decrease of systemic side effects and adverse effects.
Reduction of the number of administrations and thus improved patient compliance & ease.
Lack of explosion.
Ease of handling and insertion.
Reproducibility of release kinetics.
Sterility.
Better stability.
Exclusion of additives.
Improved shelf life with comparison to aqueous solutions due to lack of water. 5
6. MECHANISM OF DRUG RELEASE
Drug release from Ocusert involves one of following mechanisms:
• Diffusion
• Osmosis
• Bio-erosion
6
7. METHODS OF PREPARATION OF OCUSERTS
Solvent casting method
Glass substrate technique
Melt extrusion technique
7
8. S.N
o.
AUTHOR NAME TITLE & JOURNAL FINDINGS
1. Sneha prabha Lad et al.
(2016)
“Design of ocular controlled release ocuserts
of brinzolamide”, Int J Pharm 2016; 6(2):
191-202
In-vitro diffusion and In-vivo studies
revleaed 82.0% ± 0.594 & 80.00 ± 1.003%
respectively. Drug polymer compatibility
was confirmed by IR & DSC studies.
2. Sayani Bhattacharyya et
al. (2015)
“Preparation and Evaluation of Ophthalmic
Inserts of brimonidine tartrate”, IJPCBS
2015, 5(1), 177-183
It was found that Inserts containing HEMA
plasticized with DBP indicated better shape
holding properties and a controlled drug
release.
3. Narendra V et al. (2014) “Azithromycin β –cyclodextrin ocular films:
Preparation and Evaluation”, IJCPS, 2014,
Vol.2(11): 1265-1269
The prepared ocular films gave satisfactory
physicochemical characteristics and in-vitro
release characteristics
4. Vivek Dave et al. (2013) “Formulation and evaluation of controlled
delivery of Aceclofenac through ocular
insert”, Turk J Pharm Sci., 2013, 10 (2), 205-
220
It was observed that 98.24% drug was
released from the formulation consisted of
3% HPMC while it was 70.25% with 3%
Ethyl Cellulose for a period of 24 hr and
followed zero order kinetics.
8
REVIEW OF LITRATURE
9. 5. Kaul Shweta et al.
(2012)
Development and In-vitro characterization of
ocular insert containing erythromycin, IRJP
2012, 3 (8) Pg. no. 246-250
It was concluded that the Erythromycin
ocuserts would be able to offer benefits such
as increased residence time, prolonged drug
release, reduced frequency of administration,
and thereby might help to improve patient
compliance.
6. T.K. Ghelani et al.
(2011)
Formulation and Evaluation of Timolol
Maleate Ocular Insert, Asian Journal of
Biochemical and Pharmaceutical Research
2011, (1), 167-174
In-vitro release study was carried out for all
formulations and overall results revealed that
as concentration of polymer increased, the
drug release was decreased.
7. A. Rajasekaran et al.
(2010)
Design and evaluation of polymeric
controlled release Natamycin ocular inserts,
Kathmandu university journal of science,
engineering and technology 2010, 6 (I),108-
115
FTIR studies indicated no possibility of
interaction between drug and polymer and all
formulations showed no change in physical
appearance. The formulation consisted of 3%
Eudragit RL 100 and 1% Eudragit L 100
showed expected zero order release for one
day.
9
10. 8. Hitesh B. Gevariya et al.
(2009)
Sustained ophthalmic delivery of
levofloxacin from once a day ocuserts,
International Journal of Pharmacy and
Pharmaceutical Sciences, 1 (1), Nov.-Dec.
2009 pg. no. 24-32
In-vitro drug release studies revealed that,
the formulation with PEO/EC (3:7) was
found to be better than the other
formulations . The formulation L6 followed
perfect zero order kinetics release (n=1.03)
while rest of formulations released super
case II kinetics (n>1).
9. Shreenivas et al. (2006) Ofloxacin ocular inserts: Design,
Formulation and Evaluation, IJPT 5:159-
162, 2006
Best formulation showed maximum
cumulative percentage drug release of 91.27
% at the end of 24 hr. Prepared ocuserts
were also passed the test for sterility &
showed zero-order drug release in the in-
vitro and in-vivo release studies.
10. Venkateshwar RAO et al. Preparation and Evaluation of Ocular
Inserts Containing Norfloxacin, Turk J
Med Sci 34 (2004) 239-246
All the prepared films were found to be
uniform in thickness and the partition
coefficient of norfloxacin and its beta
cyclodextrin complex was 0.048 and 0.853
respectively. I.R. spectra revealed
complexation of norfloxacin with b-
cyclodextrin.
10
12. • PREPARATION OF OCUSERTS
S.No. Ingredient Amount
1. Ciprofloxacin HCL 100 mg
2. Poly Vinyl Pyrrolidone (K-30) 500 mg
3. Poly Vinyl Alcohol 500 mg
4. Poly Ethylene Glycol 400 0.5 ml
5. Glycerine 25 mg
Ocusert of ciprofloxacin was prepared
with three different polymers by solvent
casting method.
12
13. • EVALUATION OF OCUSERTS OF CIPROFOLAXCIN:
Percentage (%) moisture absorption
Percentage (%) moisture loss
Uniformity of thickness
Uniformity of weight
Drug content
In vitro drug release studies
13
14. EXPERIMENTAL STUDIES:
• Spectrophotometric scan of Ciprofloxacin HCl:
The λmax of ciprofloxacin hcl was found to be 278nm.
U.V scan of Ciprofloxacin HCl in 0.1N HCl
14
RESULT AND DISCUSSION
15. • Validation of λmax
Overlain spectra of ciprofloxacin HCl
15
16. Preparation of standard curve of ciprofloxacin HCl:
S.
No.
Concentration
(µg/ml)
Absorbance
1. 2 0.195
2. 4 0.389
3. 6 0.598
4. 8 0.795
5. 10 0.989
0
0.195
0.389
0.598
0.795
0.989
y = 0.0993x - 0.0024
R² = 0.9999
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
Absorbance
Concentration (µg/ml)
Caliberation curve of Ciprofloxacin HCl
Concentration v/s absorbance data of
Ciprofloxacin HCl in 0.1N HCl
Calibration curve of Ciprofloxacin HCl in
0.1N HCl
16
17. DRUG - EXCIPIENT COMPATIBILITY STUDY BY FTIR
FTIR scan of Ciprofloxacin HCl (pure drug) FTIR scan of formulation blend
17
18. EVALUATION OF OCUSERTS:
• Percentage (%) moisture absorption:
The percentage (%) moisture absorption of ocusert was observed to be 26%.
• Percentage (%) moisture loss:
The percentage (%) moisture loss of ocusert was observed to be 27%
• Uniformity of thickness:
The mean thickness of ocusert measured at different points was found to be 0.124mm.
• Uniformity of weight:
The weight of ocusert was observed to be in the range of 12.2 - 12.6mg. It showed great
distribution of the drug, polymer and plasticizer.
• Drug content:
The drug content of ocular insert was found to be 99.89%.
18
19. • In vitro drug release study of Ocusert of Ciprofloxacin HCl:
Sr.
No.
Time
(hrs.)
Absorbance Concentrati
on (µg/ml)
Amt. in
30ml
% Drug
Release
1. 1 0.191 1.923 0.577 8.127
1. 2 0.212 2.135 0.640 9.021
1. 3 0.363 3.655 1.097 15.447
1. 4 0.620 6.244 1.873 26.382
1. 5 0.732 7.372 2.212 31.148
1. 6 0.803 8.087 2.425 34.169
1. 7 0.898 9.043 2.713 38.211
1. 8 0.988 9.949 2.984 41.969Percentage drug release from Ciprofloxacin HCl Ocusert
0
5
10
15
20
25
30
35
40
45
0 1 2 3 4 5 6 7 8 9
%DrugRelease
Time (hr.)
In-vitro Drug Release form Ciprofloxacin Ocusert
19
20. CONCLUSION
This project title “Formulation and Evaluation of ocuserts of ciprofloxacin HCl” revealed following results:
• Compatibility study using FTIR was performed to check the compatibility of drug with various excipient.
Characteristics peaks obtained with pure drug were compared with that produced with different excipients that
confirmed the compatibility of drug with excipients.
• Ocusert of ciprofloxacin HCl was prepared using different material i.e., PVP K-30, PVA, PEG 400 and glycerin.
• Prepared ocuserts were evaluated for various parameters viz., Percentage moisture loss, percentage moisture
absorbs, thickness, weight variation, drug content and in-vitro diffusion.
• The percentage (%) moisture absorption and loss of ocular insert were found to be 26% and 27% respectively.
• The thickness of ocular insert was found to be uniformed and its mean while measuring at different points was found
to be 0.124mm.
• The weight of ocular inserts was found to be in the range of 12.2 - 12.6mg which indicated decent distribution of the
drug, polymer and plasticizer.
• The drug content of ocular insert was found to be 99.89%.
• Percentage drug release from ciprofloxacin HCl ocusert was found to be 41.969% in 8 hr.
It was concluded that prepared ocusert of ciprofloxacin HCl could be a better alternative to conventional ocular
formulations that retained on ocular surface for longer duration and released drug in controlled manner.
20
21. REFERENCES
• Jitendra, sharma P.K, banik A., Dixit S. A new trend: ocular drug delivery system. International journal of pharmaceutical sciences 2011;
2(3):1-2.
• Http://anatomy.Iupvi.Edu
• www.Aioeyesurgeons.Com
• www.Myeyeworld.Com
• Patel hitesh A, patel jayavadan K., Patel kalpesh N, patel ravi R. Ophthalmic drug delivery system-a review. Scholars research library
2010; 2(4): 103.
• Williams Lippincott and Wilkens, Remington - the science and practice of pharmacy, 21st edition, 2005, published by wolters kluwer
company, page no. 850, 851 & 857
• Yie.W. Chien, novel drug delivery systems 2nd edition,1982,100-120.
• Kaul shweta, kumar g., Kothiyal P. An insight into ocular insert. International journal of pharmaceutical sciences and research 2012;
3(7):1907-1908.
• Tangri p, khurana s. Basics of ocular drug delivery systems. International journal of research in pharmaceutical and biomedical sciences
2011; 2(4): 1547.
• Heller j. Controlled release of biologically active compounds from bio erodible polymers. Biomaterials 1980; 1:51-7. 21